MDPI and ACS Style
Hilser, T.; Darr, C.; Niegisch, G.; Schnabel, M.J.; Foller, S.; Häuser, L.; Zschäbitz, S.; Lewerich, J.; Ivanyi, P.; Schlack, K.;
et al. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project. Cancers 2024, 16, 2998.
https://doi.org/10.3390/cancers16172998
AMA Style
Hilser T, Darr C, Niegisch G, Schnabel MJ, Foller S, Häuser L, Zschäbitz S, Lewerich J, Ivanyi P, Schlack K,
et al. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project. Cancers. 2024; 16(17):2998.
https://doi.org/10.3390/cancers16172998
Chicago/Turabian Style
Hilser, Thomas, Christopher Darr, Günter Niegisch, Marco Julius Schnabel, Susan Foller, Lorine Häuser, Stefanie Zschäbitz, Jonas Lewerich, Philipp Ivanyi, Katrin Schlack,
and et al. 2024. "Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project" Cancers 16, no. 17: 2998.
https://doi.org/10.3390/cancers16172998